Technology Intended To Reduce Failure Rates Of In Vitro Fertilization and

Intrauterine Insemination Procedures

LA JOLLA, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Duska Therapeutics,
Inc. (OTC Bulletin Board: DSKA) announced today that it has entered into a
series of agreements to acquire exclusive worldwide rights from several
inventors to develop and commercialize technologies relating to the use of
adenosine 5'-triphosphate (ATP) to improve motility of human and animal
sperm. ATPotent is a novel ATP-based sperm processing medium designed to
reduce failure rates of in vitro fertilization (IVF) and intrauterine
insemination (IUI) procedures.

Male factor infertility is implicated in about half of the six million
infertile couples in the US. Lack of, or low sperm motility or movement,
also known as asthenozoospermia, is a common cause of human male
infertility. It has been reported in the medical literature that the
prevalence of asthenozoospermia in infertile men is approximately 82
percent. Currently, there is no FDA-approved product that enhances sperm
motility.

Duska's sponsored studies at the University of Pennsylvania and the
University of Padua (Italy) have shown that ATP treatment of poorly motile
human sperm in vitro (outside of the human body) resulted in improved
motility parameters and increased frequency of hyperactivated sperm. The
improved motility parameters were also observed in human sperm derived from
males with asthenozoospermia and in thawed cryopreserved human sperm.

Results from these recent studies support earlier observations from a
non-Duska sponsored European study in which increased success rate of IVF
procedures were observed when ATP-treated sperm derived from infertile
males with asthenozoospermia were used.

Duska Therapeutics, Inc. (Duska) is a specialty pharmaceutical company
that develops new cardiovascular medicines based upon the emerging new
pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These
two molecules play critical roles in cellular metabolism and signal
transduction, the manipulation of which by several pharmaceuticals
constitute novel therapeutic modalities for the treatment of major
cardiovascular disorders. Duska is developing a portfolio of
investigational medicines, two of which are in late stages of clinical
testing. Duska's ATPace is expected to enter a pivotal Phase 3 clinical
trial for the treatment of paroxysmal supraventricular tachycardia. Duska's
CDP-1050 is expected to commence a Phase 2 clinical trial for the treatment
of heart failure. In addition, Duska has a preclinical program to develop
new chemical entities that target a newly discovered pathway in the
pathophysiology of chronic obstructive pulmonary disease. For more
information, visit http://www.duskatherapeutics.com.

Forward-looking Statements

This press release contains forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as amended
that involve risks and uncertainties that could cause actual events or
results to differ materially from the events or results described in the
forward-looking statements. The forward-looking statements are based on
current expectations, estimates and projections made by management. Duska
intends for the forward-looking statements to be covered by the safe harbor
provisions for forward-looking statements. Words such as "anticipates,"
"expects," "intends," "plans," "believes," "seeks," "estimates," or
variations of such words are intended to identify such forward-looking
statements. All statements in this release regarding the future outlook
related to Duska are forward-looking statements, including the statements
that Duska's ATPace is expected to enter a pivotal Phase 3 clinical trial,
Duska's CDP-1050 is expected to commence a Phase 2 clinical trial, the
belief that the newly acquired proprietary technology substantially
strengthens the value of our ATPotent program and will allow us to address
a pressing medical need in artificial reproductive technologies. The
forward-looking statements are subject to risks and uncertainties that
could cause actual results to differ materially from those set forth or
implied by any forward-looking statements. Such risks include the risk that
the clinical trial for approval of ATPace and the Phase 2 clinical trial
for our CDP-1050 may not be successful and that the newly acquired
proprietary technology may not lead to expected results including the
development or the successful commercialization of technologies relating to
the use of ATP to improve motility of sperm. Additional uncertainties and
risks are described in Duska's most recently filed SEC documents, such as
its most recent annual report on Form 10-KSB, all quarterly reports on Form
10-QSB and any current reports on Form 8-K filed since the date of the last
Form 10-KSB. Copies of these filings are available through the SEC website
at http://www.sec.gov. All forward-looking statements are based upon
information available to Duska on the date hereof. Duska undertakes no
obligation to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise, other
than as required by law.

(Date:12/9/2016)... NY (PRWEB) , ... December 09, 2016 , ... ... and Drug Dependence, Inc. (NCADD) is recommending the film Whispering Spirits ... and the District of Columbia as an education tool in the war against teen ...

(Date:12/9/2016)... ... December 09, 2016 , ... An inventor from Cana, Va., wanted ... all types of amusement park rides. , The patent-pending SAFETY STRAP FOR AMPUTEES improves ... use and could be set up in a matter of minutes, or even seconds. ...

(Date:12/9/2016)... ... 09, 2016 , ... The Holy Name Medical Center Foundation ... on December 3rd, to benefit Holy Name Medical Center's programs and services. More ... over $1 million - the largest event in the Center's history, both in ...

(Date:12/9/2016)... ... December 09, 2016 , ... "I had a terrible time trying to get ... thought that if the nebulizer had a more child-friendly design, then children would be ... developed the patent-pending NEBY to avoid the need to deliver medication via a nebulizer ...

(Date:12/8/2016)... 2016 KEY FINDINGS The global ... 2017-2023. Various reasons for growth of the medical lifting ... of chronic diseases, high recovery cost of injuries and ... Medical lifting sling refers to an assistive device that ... slings connect to the lift and hold the patient. ...

(Date:12/8/2016)... Lilly and Company (NYSE: LLY ) today ... at the 9 th Clinical Trials on Alzheimer,s ... meet the primary endpoint in the EXPEDITION3 clinical trial, ... dementia due to Alzheimer,s disease (AD), and Lilly will ... of mild dementia due to AD. ...